Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 3 nice upbeat articles within a week from Baystreet.....

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Sep 26, 2023 10:35pm

176 Views

Post# 35656080

RE:RE:3 nice upbeat articles within a week from Baystreet.....

I look forward to seeing buckhenry drowning in his shorts
A $5 million gift & his is still producing a sea of nothingness.
open statements with know substance. You are loosing all credibility.
Today it was announced that the leading Pancreatic cancer organization in th3 USA PaCan, ...after much consideration & due diligence awarded $5 million to ONC to add another co- therapy.
That will not delay the existing phase 3 , invite.
Yes, the 90 day window is late. Why rush a deal when the trial organizers just gave a nice $$$ vote of confidence.
Stay tuned , more to come...